Saquinavir

Saquinavirum

For medical students2 min readUpdated 2026-10-10

Saquinavir was the first HIV protease inhibitor antiviral introduced into clinical practice in the mid-1990s. The drug effectively suppresses human immunodeficiency virus replication, though it requires careful management of complex pharmacokinetic interactions.

Pharmacological groupAntiviral agents (HIV protease inhibitors)

Dosage formCapsules, 0.2 g

Route and doseOral, 0.6 g

Historical statusFirst protease inhibitor (mid-1990s)

Mechanism of Action

Saquinavir belongs to the class of HIV protease inhibitors. The drug blocks a specific viral enzyme, thereby disrupting the maturation of viral particles. Membrane transporters play a critical role in saquinavir pharmacokinetics, notably P-glycoprotein (a member of the ATP-binding cassette ABC transporter family). P-glycoprotein is localized on the apical membrane of the placental syncytiotrophoblast and exerts a protective role by pumping lipophilic compounds (including HIV protease inhibitors) back into the maternal circulation, thereby preventing their penetration to the fetus.

Pharmacological Effects

As a substrate for P-glycoprotein, saquinavir undergoes active transmembrane transport. When co-administered with P-glycoprotein inhibitors (such as Chinidinum [quinidine], Lidocainum [lidocaine], Verapamilum [verapamil]), this placental barrier defense is weakened, facilitating drug penetration across histohematic barriers and increasing fetal toxicity. Saquinavir pharmacokinetics are also modulated by the hepatic and intestinal cytochrome P450 isozyme CYP3A4, the activity of which can be manipulated to enhance drug bioavailability.

Indications

The drug is prescribed as part of combination antiretroviral therapy (cART) for HIV infection. Historically, protease inhibitors required frequent administration (three times daily or more); however, to optimize dosing regimens and reduce pill burden, pharmacological boosters (ritonavir boosting) are used to inhibit CYP3A4 and reduce presystemic elimination.

Adverse Effects and Contraindications

The primary safety consideration when prescribing saquinavir is drug-drug interactions. Concurrent administration with P-glycoprotein inhibitors blocks the protective efflux mechanism in the placenta, elevating the risk of fetal toxicity. Sex and genetic factors contributing to pharmacokinetic variability must also be considered: P-glycoprotein gene expression in males is more than double that in females, influencing individual pharmacokinetics.

Clinical Administration

Saquinavir is available in 0.2 g capsules. The standard oral dose is 0.6 g. Most protease inhibitors exhibit improved absorption when taken with food. To overcome rapid first-pass metabolism, saquinavir is frequently co-formulated or co-administered with low-dose ritonavir, which acts less as an active antiviral and more as a pharmacokinetic booster that suppresses presystemic elimination.

Mnemonic

"Saquinavir is the first among proteases" (introduced in the mid-1990s as the pioneer of the HIV protease inhibitor class).

Frequently asked questions

What specific adverse effects are associated with saquinavir?

With prolonged use, saquinavir can cause metabolic, renal, and hepatic adverse effects. These include metabolic disturbances such as elevated atherogenic lipoproteins and hyperglycemia, which carry a risk of type 2 diabetes mellitus. Redistribution of body fat (lipodystrophy), nephrolithiasis, and hepatotoxicity may also occur.

Lipodystrophy — Redistribution of adipose tissue
Nephrolithiasis — Renal stone formation
Hepatotoxicity — Impairment of liver function

What drug class does saquinavir belong to?

Saquinavir is the first representative of the HIV protease inhibitor class, introduced into practice in the mid-1990s.

What is the standard dosage form and reference dose?

The drug is available in 0.2 g capsules and is administered orally at a dose of 0.6 g.

What is the protective role of placental P-glycoprotein during saquinavir therapy?

P-glycoprotein located on the apical membrane of the trophoblast pumps protease inhibitors unidirectionally back into maternal blood, protecting the fetus from toxic exposure.

What is the mechanism behind the "booster" effect of ritonavir when combined with protease inhibitors?

Ritonavir inhibits the CYP3A4 isozyme in the liver and gut wall, decreasing presystemic elimination and increasing the bioavailability of the primary drug.

Go deeper

Structure and function of placental ATP-binding cassette (ABC) transporters
Pharmacokinetic interactions between HIV protease inhibitors and CYP3A4 substrates
Sex and genetic differences in P-glycoprotein expression
The role of ritonavir as a pharmacokinetic enhancer (booster)
The effect of food intake on the absorption of protease inhibitors